WWM
GLMD icon

Western Wealth Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Western Wealth Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-164
Closed -$12.6K – 656
2023
Q1 		$12.6K Hold
164
– – ﹤0.01% 639
2022
Q4 		$14.8K Sell
164
-164
-50% -$10.7K ﹤0.01% 606
2022
Q3 		$19K Hold
328
– – ﹤0.01% 803
2022
Q2 		$38K Buy
+328
New +$54.4K ﹤0.01% 777

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TFGT
TS Financial Group (TSFG) Lake Forest, Illinois $794M AUM 24.65% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BCM
Bourgeon Capital Management Darien, Connecticut $679M AUM 50.89% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Western Wealth Management's GLMD Position: Q2 2023 in Review

Western Wealth Management sold out of Galmed Pharmaceuticals (GLMD) in Q2 2023, closing a stake of 164 shares — an estimated $12.6K sold.

Western Wealth Management first reported a position in GLMD in Q2 2022 and held it in 4 quarters. The position peaked at $38K in Q2 2022. 11 funds tracked by Wall St. Rank hold GLMD as of Q2 2023.

  • Western Wealth Management reported no remaining Galmed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Western Wealth Management sold 164 Galmed Pharmaceuticals shares in Q2 2023, an estimated $12.6K.
  • Western Wealth Management first reported a position in Galmed Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • Western Wealth Management's Galmed Pharmaceuticals position peaked at $38K in Q2 2022.
  • 11 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2023.

Based on Western Wealth Management's 13F filing for Q2 2023, filed 30 Aug 2023.